Other promising combinations in RAS-driven neuroblastoma include a MEK inhibitor with retinoic acid [7,15,16], a CENPE inhibitor [17], a Hippo pathway modulator [18], a SHP2 inhibitor [19], and a CDK8 inhibitor [20]. Here, MAP2K7 is linked to neuroblastoma.